Previous
Poster Home
Next
Optimal Interval Between Immune Therapy and Targeted Therapy with Sotorasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer
07:30am - 03:45pm EDT - March 31, 2023
Information
Resources
Play Recording
https://jnccn.org/view/journal...
Author(s):
Julia Bielanin, BS, BA
, Medical Student, Vanderbilt-Ingram Cancer Center
Tags:
Member Institution
Clinical Oncology
Display Label
Action
048-General Poster Session
Download Handout